Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report released on Sunday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

NYSE:OGEN opened at $0.30 on Friday. The company has a 50-day moving average of $0.33 and a 200-day moving average of $0.50. The company has a market capitalization of $3.64 million, a price-to-earnings ratio of -0.04 and a beta of 0.38. Oragenics has a 52 week low of $0.25 and a 52 week high of $3.89.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.